


**Amendments to the Claims**

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Previously Presented) A compound of formula I




wherein

R<sub>a</sub> is H; C<sub>1-4</sub>alkyl; or C<sub>1-4</sub>alkyl substituted by OH, NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl or N(di-C<sub>1-4</sub>alkyl)<sub>2</sub>;

R<sub>b</sub> is H; halogen; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkoxy, and

R is a radical of formula (a)



(a)


wherein

R<sub>1</sub> is piperazine; and

R<sub>2</sub> is H; halogen; C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkoxy; CF<sub>3</sub>; nitrile; nitro or amino, or a salt thereof.


2. (Original) A compound according to claim 1 wherein R<sub>a</sub> is H, methyl, ethyl, or isopropyl, or a salt thereof.
3. (Previously Presented) A compound according to claim 1 wherein R<sub>b</sub> is H, Cl, methyl or ethyl, or a salt thereof.
4. (Previously Presented) A compound according to claim 1 wherein R<sub>1</sub> is a piperazinyl, substituted on a ring nitrogen or on a ring carbon, or a salt thereof.
5. (Previously Presented) A compound according claim 1 wherein R<sub>2</sub> is H, Cl, F, CF<sub>3</sub>, nitrile, nitro or amino, or a salt thereof.

6. (Previously Presented) A process for the preparation of a compound of formula I according to claim 1, which process comprises reacting a compound of formula II



wherein  $R_a$  and  $R_b$  are as defined in claim 1,

with a compound of formula III



wherein R is as defined in claim 1,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

7. (Previously Presented) A compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical.
8. (Previously Presented) A pharmaceutical composition comprising a compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.
9. (Canceled)
10. (Previously Presented) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.
11. (Previously Presented) A method for treating acute or chronic transplant rejection, psoriasis, or uveitis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.